The revenue for Imsidolimab is expected to reach an annual total of $14 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Imsidolimab Overview
Imsidolimab (ANB-019) is under development for the treatment of generalized pustular psoriasis (GPP). It is administered through the subcutaneous and intravenous route. The drug candidate acts by targeting the interleukin-36 receptor (IL-36R). It is developed based upon somatic hypermutation (SHM) Platform.
It was under development for the treatment of palmo-plantar pustular psoriasis (PPP), hidradenitis suppurativa, palmoplantar pustulosis (PPP),acne vulgaris, Ichthyosis and EGFRi/MEKi therapy mediated acneiformrash.
AnaptysBio Overview
AnaptysBio is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation and other autoimmune indications. The company develops its product candidates through its proprietary antibody discovery technology platform that is based on somatic hypermutation (SHM). The company has various product candidates under development for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis, and human autoimmune diseases. The company has partnership with GlaxoSmithKline and Bristol-Myers Squibb to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$10.3 million for the fiscal year ended December 2022 (FY2022), a decrease of 83.7% over FY2021. The operating loss of the company was US$115.2 million in FY2022, compared to an operating loss of US$56.8 million in FY2021. The net loss of the company was US$128.7 million in FY2022, compared to a net loss of US$57.8 million in FY2021. The company reported revenues of US$1.4 million for the first quarter ended March 2023, a decrease of 79.8% over the previous quarter.
For a complete picture of Imsidolimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.